IL17A and metastatic melanoma: There are, however, two case reports which have documented the utility of administration of the IL-17A-targeted MAb, secukinumab, in causing resolution of pembrolizumab-associated, severe psoriasiform dermatologic toxicity in one patient with metastatic colon cancer (139) and a second with metastatic melanoma (140).